Treatment of Atrial Fibrillation with Rapid Ventricular Response

Immediate Assessment and Management

• The American College of Cardiology recommends performing immediate direct-current cardioversion if the patient shows any signs of hemodynamic instability, including altered mental status, symptomatic hypotension, ongoing ischemia, pulmonary edema, or inadequate rate control with medications 1, 2.
• The American Heart Association suggests immediately assessing for Wolff-Parkinson-White (WPW) syndrome by examining the ECG for pre-excitation (wide QRS ≥120 ms during AFib) 1, 2, 4.

First-Line Rate Control for Hemodynamically Stable Patients

• The American College of Cardiology recommends administering IV metoprolol 2.5-5 mg bolus over 2 minutes, repeat every 5-10 minutes up to 15 mg total, or IV diltiazem 0.25 mg/kg (typically 20 mg) bolus over 2 minutes for patients with preserved left ventricular function 3.
• The American Heart Association suggests that beta-blockers (metoprolol) are preferred as first-line because they provide better exercise-induced tachycardia control and have lower failure rates than other agents 3.

Critical Contraindication: WPW Syndrome

• The American College of Cardiology recommends never administering AV nodal blocking agents (beta-blockers, calcium channel blockers, digoxin, adenosine, or amiodarone) in patients with WPW and pre-excited AFib 1, 2.
• The American Heart Association suggests that for hemodynamically unstable WPW patients, immediate cardioversion is recommended 1, 2.

Special Populations

• The American College of Cardiology recommends using nondihydropyridine calcium channel blockers (diltiazem or verapamil) exclusively in COPD patients; avoid beta-blockers 1, 2, 3.
• The American Heart Association suggests that IV beta-blockers are recommended to slow RVR in ACS patients without heart failure, hemodynamic instability, or bronchospasm 1, 2.

Combination Therapy and Refractory Cases

• The American College of Cardiology recommends that combination therapy with multiple AV nodal blocking agents may be necessary when single agents fail to achieve adequate rate control 3.
• The American Heart Association suggests that digoxin combined with beta-blocker or calcium channel blocker is reasonable to control both resting and exercise heart rate 1, 2.

Rate Control Targets

• The American College of Cardiology recommends focusing on symptom improvement, exercise tolerance, and prevention of tachycardia-induced cardiomyopathy rather than achieving arbitrary heart rate targets 3, 6.